drugset / Trial / NCT06245213
A Study of ANAVEX3-71 in Adults With Schizophrenia
Phase 2
Active not recruiting
71 enrolled
Anavex Life Sciences Corp.
COGNISION · collabCognitive Research Corporation · collabHassman Research Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
Timeline
- Start
- 2024-03-15
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ANAVEX3-71 | Unknown | 30 mg | Oral |
| Comparator | ANAVEX3-71 | Unknown | 60 mg | Oral |